Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
INR 1688.75
(1.22%)
INR 1688.75
(1.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -72.47 Billion INR | -419.82% |
| 2022 | 22.65 Billion INR | 170.42% |
| 2021 | -32.17 Billion INR | -33.83% |
| 2020 | -24.04 Billion INR | -191.14% |
| 2019 | 26.38 Billion INR | -23.57% |
| 2018 | 34.52 Billion INR | 40.33% |
| 2017 | 24.59 Billion INR | 110.43% |
| 2016 | 11.68 Billion INR | 177.26% |
| 2015 | 4.21 Billion INR | -75.31% |
| 2014 | 17.07 Billion INR | 195.13% |
| 2013 | -17.94 Billion INR | 0.67% |
| 2012 | -18.07 Billion INR | -26.52% |
| 2011 | -14.28 Billion INR | -271.75% |
| 2010 | -3.84 Billion INR | -13.75% |
| 2009 | -3.37 Billion INR | 77.34% |
| 2008 | -14.9 Billion INR | -36.06% |
| 2007 | -10.95 Billion INR | -315.52% |
| 2006 | -2.63 Billion INR | -176.28% |
| 2005 | 3.45 Billion INR | -46.39% |
| 2004 | 6.44 Billion INR | 101.27% |
| 2003 | 3.2 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 190.9 Billion INR | 363.42% |
| 2024 Q2 | -59.31 Billion INR | -128.5% |
| 2023 Q2 | -34.74 Billion INR | -122.97% |
| 2023 Q4 | -72.47 Billion INR | -148.86% |
| 2023 Q3 | 148.33 Billion INR | 526.87% |
| 2023 FY | -72.47 Billion INR | -419.82% |
| 2023 Q1 | 151.3 Billion INR | 567.72% |
| 2022 FY | 22.65 Billion INR | 170.42% |
| 2022 Q3 | 138.35 Billion INR | 18805.45% |
| 2022 Q2 | 731.8 Million INR | -99.42% |
| 2022 Q1 | 126.67 Billion INR | 493.64% |
| 2022 Q4 | 22.65 Billion INR | -83.62% |
| 2021 Q4 | -32.17 Billion INR | -130.52% |
| 2021 FY | -32.17 Billion INR | -33.83% |
| 2021 Q1 | 95.75 Billion INR | 498.24% |
| 2021 Q2 | -51.64 Billion INR | -153.93% |
| 2021 Q3 | 105.45 Billion INR | 304.19% |
| 2020 FY | -24.04 Billion INR | -191.14% |
| 2020 Q4 | -24.04 Billion INR | -125.0% |
| 2020 Q3 | 96.19 Billion INR | 2232.72% |
| 2020 Q2 | 4.12 Billion INR | -96.38% |
| 2020 Q1 | 113.84 Billion INR | 331.53% |
| 2019 Q1 | 111.82 Billion INR | 223.94% |
| 2019 FY | 26.38 Billion INR | -23.57% |
| 2019 Q4 | 26.38 Billion INR | -74.43% |
| 2019 Q3 | 103.19 Billion INR | 534.46% |
| 2019 Q2 | 16.26 Billion INR | -85.45% |
| 2018 Q3 | 144.79 Billion INR | 1313.93% |
| 2018 Q1 | 140.19 Billion INR | 469.94% |
| 2018 FY | 34.52 Billion INR | 40.33% |
| 2018 Q4 | 34.52 Billion INR | -76.16% |
| 2018 Q2 | 10.24 Billion INR | -92.7% |
| 2017 FY | 24.59 Billion INR | 110.43% |
| 2017 Q4 | 24.59 Billion INR | -83.74% |
| 2017 Q3 | 151.32 Billion INR | 1160.06% |
| 2017 Q2 | 12 Billion INR | -92.3% |
| 2017 Q1 | 155.97 Billion INR | 1234.3% |
| 2016 Q4 | 11.68 Billion INR | -91.75% |
| 2016 FY | 11.68 Billion INR | 177.26% |
| 2016 Q1 | 147.04 Billion INR | 3387.63% |
| 2016 Q2 | 6.08 Billion INR | -95.86% |
| 2016 Q3 | 141.73 Billion INR | 2229.97% |
| 2015 Q3 | 141.45 Billion INR | 313.78% |
| 2015 Q2 | -66.16 Billion INR | -150.45% |
| 2015 Q4 | 4.21 Billion INR | -97.02% |
| 2015 Q1 | 131.15 Billion INR | 668.06% |
| 2015 FY | 4.21 Billion INR | -75.31% |
| 2014 Q4 | 17.07 Billion INR | -78.67% |
| 2014 Q3 | 80.06 Billion INR | 232.3% |
| 2014 Q2 | -60.51 Billion INR | -163.12% |
| 2014 Q1 | 95.88 Billion INR | 634.19% |
| 2014 FY | 17.07 Billion INR | 195.13% |
| 2013 FY | -17.94 Billion INR | 0.67% |
| 2013 Q4 | -17.94 Billion INR | -120.88% |
| 2013 Q3 | 85.98 Billion INR | 337.31% |
| 2013 Q1 | 53.63 Billion INR | 396.84% |
| 2013 Q2 | -36.23 Billion INR | -167.55% |
| 2012 FY | -18.07 Billion INR | -26.52% |
| 2012 Q4 | -18.07 Billion INR | 0.0% |
| 2012 Q2 | -32.32 Billion INR | 0.0% |
| 2011 Q4 | -14.28 Billion INR | 0.0% |
| 2011 FY | -14.28 Billion INR | -271.75% |
| 2010 FY | -3.84 Billion INR | -13.75% |
| 2009 FY | -3.37 Billion INR | 77.34% |
| 2008 FY | -14.9 Billion INR | -36.06% |
| 2007 FY | -10.95 Billion INR | -315.52% |
| 2006 FY | -2.63 Billion INR | -176.28% |
| 2005 FY | 3.45 Billion INR | -46.39% |
| 2004 FY | 6.44 Billion INR | 101.27% |
| 2003 FY | 3.2 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 1974.598% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 2062.205% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | -2449.376% |
| Granules India Limited | 9.28 Billion INR | 880.357% |
| Indoco Remedies Limited | 6.47 Billion INR | 1219.005% |
| Achyut Healthcare Limited | -3.74 Million INR | -1934499.573% |
| Ajanta Pharma Limited | -954.9 Million INR | -7489.287% |
| Alkem Laboratories Limited | -1.6 Billion INR | -4402.927% |
| Alpa Laboratories Limited | 35.36 Million INR | 205031.991% |
| Brooks Laboratories Limited | 49.48 Million INR | 146548.621% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | -1345.805% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 2296.759% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -6159.553% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 661.218% |
| Eris Lifesciences Limited | 13.8 Billion INR | 624.903% |
| FDC Limited | -57.75 Million INR | -125385.005% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | -1591.148% |
| Gufic Biosciences Limited | 3.19 Billion INR | 2368.72% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | -1644.983% |
| Ipca Laboratories Limited | 11.41 Billion INR | 734.856% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -5113.939% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 3849.253% |
| Lasa Supergenerics Limited | 205.79 Million INR | 35314.02% |
| Laurus Labs Limited | 24.38 Billion INR | 397.196% |
| Lupin Limited | 17.19 Billion INR | 521.526% |
| Mankind Pharma Limited | -9.9 Billion INR | -631.431% |
| Medicamen Biotech Limited | 160.31 Million INR | 45304.534% |
| Medico Remedies Limited | 78.67 Million INR | 92210.909% |
| Megasoft Limited | 1.28 Billion INR | 5737.275% |
| NATCO Pharma Limited | -5.81 Billion INR | -1145.833% |
| Piramal Pharma Limited | 42.27 Billion INR | 271.421% |
| RPG Life Sciences Limited | -364.7 Million INR | -19771.154% |
| Sigachi Industries Limited | 859.94 Million INR | 8527.256% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 50087.653% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 156924.349% |
| Unichem Laboratories Limited | 931.91 Million INR | 7876.463% |
| Wanbury Limited | 1.1 Billion INR | 6653.191% |
| Windlas Biotech Limited | -273.04 Million INR | -26441.935% |
| ZIM Laboratories Limited | 983.6 Million INR | 7467.813% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 1952.508% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -7594.85% |
| Divi's Laboratories Limited | -39.77 Billion INR | -82.223% |
| Hester Biosciences Limited | 2.29 Billion INR | 3263.611% |
| Procter & Gamble Health Limited | -2.34 Billion INR | -2986.461% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -29028.79% |
| Bal Pharma Limited | 1.26 Billion INR | 5835.386% |
| Strides Pharma Science Limited | 23.25 Billion INR | 411.606% |
| Venus Remedies Limited | -267.7 Million INR | -26971.386% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 2874.612% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 1276.978% |
| Shilpa Medicare Limited | 9.06 Billion INR | 899.05% |
| Aarti Drugs Limited | 5.54 Billion INR | 1406.144% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -6480.414% |
| Suven Life Sciences Limited | -1.63 Billion INR | -4338.671% |
| Ind-Swift Limited | 9.5 Billion INR | 862.154% |
| Valiant Laboratories Limited | -295.03 Million INR | -24463.471% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 2668.769% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 822.605% |
| Themis Medicare Limited | 764.96 Million INR | 9573.686% |
| Hikal Limited | 7.96 Billion INR | 1009.628% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 327.679% |
| Sequent Scientific Limited | 4.17 Billion INR | 1834.303% |
| Novartis India Limited | -5.89 Billion INR | -1130.162% |
| Wockhardt Limited | 18.27 Billion INR | 496.662% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 367.694% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -392777.047% |
| Neuland Laboratories Limited | -214.05 Million INR | -33755.357% |
| Morepen Laboratories Limited | -231.17 Million INR | -31248.724% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 60472.129% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 7526.653% |